Despite conflicting data regarding the pharmacological management of Borderline Personality Disorder (BPD), a recent ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

Backing out revenue for its olanzapine portfolio Zyprexa ... a triple agonist targeting GIP, GLP-1, and Glucagon receptors.

Additional information showing success in the use of quetiapine for treatment of comorbid schizophrenia, alcohol, and drug dependence suggests that other dopaminergic agents may play important ...

TEV’749 is a long-acting formulation of olanzapine, one of the most widely used atypical antipsychotic schizophrenia treatments to date. The drug was first approved in the 1990s and is currently ...